CYP3A5 polymorphism and sensitivity of blood pressure to dietary salt in Japanese men

被引:24
|
作者
Zhang, L. [1 ,2 ]
Miyaki, K. [3 ]
Wang, W. [2 ]
Muramatsu, M. [1 ,2 ]
机构
[1] Tokyo Med & Dent Univ, Dept Mol Epidemiol, Med Res Inst, Chiyoda Ku, Tokyo 1010062, Japan
[2] Capital Med Univ, Sch Publ Hlth & Family Med, Dept Epidemiol & Biostat, Beijing, Peoples R China
[3] Keio Univ, Sch Med, Dept Prevent Med Cerebrovasc Dis, Shinjuku Ku, Tokyo, Japan
基金
中国国家自然科学基金;
关键词
CYP3A5; polymorphism; salt intake; blood pressure; interaction; SEQUENCE DIVERSITY; GENOTYPE; HUMANS; SODIUM; HYPERTENSION; ASSOCIATION; EXPRESSION; POTASSIUM; ADULTS; GENE;
D O I
10.1038/jhh.2009.74
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The cytochrome P-450 3A5 (CYP3A5) gene has recently been implicated in renal sodium reabsorption and blood pressure regulation. The genetic effect of CYP3A5*1 (expressor) and *3 (reduced-expressor) variants on blood pressure has been studied in African Americans and Caucasians, but not yet in the Asian population. In this cross-sectional study, 238 Japanese male workers were examined to determine whether CYP3A5 *1*3 affects the blood pressure level, taking daily salt intake into account as a potential gene-environment interaction. The A6986G polymorphism was determined by melting curve analysis, and the salt intake level was inferred from spot urine specimen by calculating 24-h urinary sodium excretion. CYP3A5 *1*3 per se had no association with systolic blood pressure (SBP) and only a weak association was detected for diastolic blood pressure (DBP) (*1/*1 vs *3/*3, P=0.038), which was strengthened after adjustment with age and body mass index (*1/*1 vs*3/*3, P=0.007; *1/*1 vs*1/*3, P=0.045). Significant interactions between the genotype and salt intake were observed in both SBP (P=0.046) and DBP (P=0.003). SBP and DBP were significantly associated with the level of salt intake in*3/*3 (P<0.001) but not in *1 carriers. *1carrier had higher blood pressure than *3/*3, but only in those with low salt intake. These results suggest that CYP3A5 variants may be a determinant of salt sensitivity of blood pressure in Japanese men. Journal of Human Hypertension (2010) 24, 345-350; doi:10.1038/jhh.2009.74; published online 8 October 2009
引用
收藏
页码:345 / 350
页数:6
相关论文
共 50 条
  • [41] CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression
    Pasari, Amit S.
    Balwani, Manish R.
    Gurjar, Prasad
    Bawankule, Charulata
    Bhawane, Amol
    Tolani, Priyanka
    Kashiv, Pranjal
    Dubey, Shubham
    Katekhaye, Vijay M.
    TRANSPLANTATION PROCEEDINGS, 2023, 55 (05) : 1305 - 1309
  • [42] Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro
    Dai, Y
    Hebert, MF
    Isoherranen, N
    Davis, CL
    Marsh, C
    Shen, DD
    Thummel, KE
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (05) : 836 - 847
  • [43] Selective expression of CYP3A5 and not CYP3A4 in human blood
    Janardan, SK
    Lown, KS
    SchmiedlinRen, P
    Thummel, KE
    Watkins, PB
    PHARMACOGENETICS, 1996, 6 (05): : 379 - 385
  • [44] CYP3A5*3 Polymorphism May Influence the Concentration of Valproic Acid
    Wang, Yan
    Li, Zhiping
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2017, 13 (05) : 495 - 500
  • [45] CYP3A5 and not CYP3A4 is present in peripheral blood.
    Janardan, SK
    Lown, KS
    SchmiedlinRen, P
    Watkins, PB
    GASTROENTEROLOGY, 1996, 110 (04) : A1222 - A1222
  • [46] Does the CYP3A5*3 polymorphism affect in vivo drug elimination?
    Thummel, KE
    PHARMACOGENETICS, 2003, 13 (10): : 585 - 587
  • [47] No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam
    D. Tomalik-Scharte
    O. Doroshyenko
    J. Kirchheiner
    A. Jetter
    A. Lazar
    T. Klaassen
    D. Frank
    C. Wyen
    G. Fätkenheuer
    U. Fuhr
    European Journal of Clinical Pharmacology, 2008, 64 : 1033 - 1035
  • [48] CYP3A5 polymorphism in kidney transplantation: individualizing tacrolimus dosing
    Pasari, Amit S.
    Balwani, Manish R.
    Bawankule, Charulata
    Sejpal, Kapil
    Gurjar, Prasad
    Kashiv, Pranjal
    Dubey, Shubham
    Malde, Sunny
    Gupta, Sushrut
    Pawar, Twinkle
    TRANSPLANTATION, 2024, 108 (09) : 170 - 170
  • [49] No effect of CYP3A5 polymorphism on intestinal or hepatic metabolism of midazolam
    Tomalik-Scharte, D
    Doroshyenko, O
    Kirchheiner, J
    Jetter, A
    Lazar, A
    Klaassen, T
    Frank, D
    Fuhr, U
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (09) : 721 - 721
  • [50] EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS DOSE AND BLOOD LEVELS IN RENAL TRANSPLANTATION IN CLINICAL PRACTICE
    Gillet, E.
    Charbonnier-Beaupel, F.
    Arzouk, N.
    Funck-Brentano, C.
    Hulot, J. S.
    Barrou, B.
    Zahr, N.
    TRANSPLANT INTERNATIONAL, 2013, 26 : 29 - 29